{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:36:49Z","timestamp":1770820609259,"version":"3.50.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2017YFC0909900"],"award-info":[{"award-number":["2017YFC0909900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Given that vaccine-induced adverse effects were mostly based on previous laboratory research and clinical trials, real-world data on the safety of coronavirus disease 2019 (COVID-19) vaccination were lacking. This study reported the adverse events (AEs) among inactivated COVID-19 vaccine recipients. Data were collected from a total of 2,808 hospital employees and their family members in Wuhan, China, with all of them receiving the first dose of inactivated COVID-19 vaccines from two pharmaceutical companies. The first dose was given between 29th April and 13th May 2021.\u00a0A total of 2,732 vaccinees received the second dose between 27th May and 8th July 2021. The whole process of receiving the vaccine was monitored by clinical pharmacists, and the information on AEs including demographics, occurrence, types, and severity was recorded through an online questionnaire and telephone follow-up. Most of the common AEs were mild and tolerable, and the overall incidence of AEs was lower than the data from the safety profile in clinical trials. Moreover, the incidence of AEs in the first dose (21.30%, 598) was higher than that in the second dose (16.07%, 439). Furthermore, the first injection had more severe AEs (4, 0.14%) than the second injection (2, 0.07%). The AEs involved the skin, muscle, respiratory tract, gastrointestinal tract, cardiovascular system, and other tissues and systems. The most common AE was pain at the injection site (first dose: 10.19%, second dose: 12.55%). All the vaccinees with AEs for both doses recovered fully in the end. It was noted that some AEs might cause blood coagulation disorder and bleeding risk. Therefore, ongoing monitoring of AEs after COVID-19 vaccination is essential in evaluating the benefits and risks of each vaccine.<\/jats:p>","DOI":"10.3389\/fimmu.2022.882919","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T04:53:27Z","timestamp":1662353607000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety monitoring in inactivated COVID-19 vaccines by clinical pharmacists from a single center in China"],"prefix":"10.3389","volume":"13","author":[{"given":"Min","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-020-11061-5","article-title":"Detection technologies and recent developments in the diagnosis of covid-19 infection","volume":"105","author":"Rai","year":"2021","journal-title":"Appl Microbiol Biotechnol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of sars-Cov-2 and covid-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-01146-0","article-title":"China's covid vaccines are going global - but questions remain","volume":"593","author":"Mallapaty","year":"2021","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7018e2","article-title":"Safety monitoring of the janssen (Johnson & Johnson) covid-19 vaccine - united states, march-April 2021","volume":"70","author":"Shay","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-00409-0","article-title":"Why covid vaccines are so difficult to compare","volume":"591","author":"Ledford","year":"2021","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.2021.8565","article-title":"Effect of 2 inactivated sars-Cov-2 vaccines on symptomatic covid-19 infection in adults: A randomized clinical trial","volume":"326","author":"Al Kaabi","year":"2021","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated sars-Cov-2 vaccine, bbibp-corv: A randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41590-020-00845-6","article-title":"Trained immunity, tolerance, priming and differentiation: Distinct immunological processes","volume":"22","author":"Divangahi","year":"2021","journal-title":"Nat Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-020-0310-6","article-title":"Qualitative sex differences in pain processing: Emerging evidence of a biased literature","volume":"21","author":"Mogil","year":"2020","journal-title":"Nat Rev Neurosci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4415\/ANN_16_02_09","article-title":"Gender differences in pain and its relief","volume":"52","author":"Pieretti","year":"2016","journal-title":"Ann Ist Super Sanita"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/all.14761","article-title":"Covid-19 vaccines and the role of other potential allergenic components different from peg. a reply to: \"Other excipients than peg might cause serious hypersensitivity reactions in covid-19 vaccines\"","volume":"76","author":"Cabanillas","year":"2021","journal-title":"Allergy"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/all.14722","article-title":"Covid-19 vaccine anaphylaxis: Peg or not","volume":"76","author":"Krantz","year":"2021","journal-title":"Allergy"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/all.14774","article-title":"Other excipients than peg might cause serious hypersensitivity reactions in covid-19 vaccines","volume":"76","author":"Borgsteede","year":"2021","journal-title":"Allergy"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31757-8","article-title":"Effects of a major deletion in the sars-Cov-2 genome on the severity of infection and the inflammatory response: An observational cohort study","volume":"396","author":"Young","year":"2020","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3233\/JAD-200831","article-title":"Covid-19: Review of a 21st century pandemic from etiology to neuro-psychiatric implications","volume":"77","author":"Yamamoto","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2020.08.011","article-title":"The novel coronavirus disease-2019 (Covid-19): Mechanism of action, detection and recent therapeutic strategies","volume":"551","author":"Seyed Hosseini","year":"2020","journal-title":"Virology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-020-00771-8","article-title":"The S1 protein of sars-Cov-2 crosses the blood-brain barrier in mice","volume":"24","author":"Rhea","year":"2021","journal-title":"Nat Neurosci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2852-1","article-title":"Sars-Cov-2 neutralizing antibody structures inform therapeutic strategies","volume":"588","author":"Barnes","year":"2020","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.05.028","article-title":"Interaction of the spike protein rbd from sars-Cov-2 with Ace2: Similarity with sars-cov, hot-spot analysis and effect of the receptor polymorphism","volume":"527","author":"Othman","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"B20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.arcmed.2020.09.010","article-title":"Coronavirus disease (Covid-19): Current status and prospects for drug and vaccine development","volume":"52","author":"Ita","year":"2021","journal-title":"Arch Med Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e64909","DOI":"10.7554\/eLife.64909","article-title":"Convalescent covid-19 patients are susceptible to endothelial dysfunction due to persistent immune activation","volume":"10","author":"Chioh","year":"2021","journal-title":"Elife"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.882919\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T04:53:32Z","timestamp":1662353612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.882919\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2022.882919"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.882919","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]},"article-number":"882919"}}